000			04084nam a22005537a 4500
008			210310s20212021 xxu||||| |||| 00| 0 eng d
022			_a2048-8726
024			_a10.1093/ehjacc/zuaa032 [doi]
024			_a6127326 [pii]
040			_aOvid MEDLINE(R)
099			_a33587752
245			_aEffect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis.
251			_aEuropean Heart Journal: Acute Cardiovascular Care. 10(8):829-839, 2021 Oct 27.
252			_aEurop Heart J Acute Cardiovasc Care. 10(8):829-839, 2021 Oct 27.
252			_zEurop Heart J Acute Cardiovasc Care. 2021 Feb 04
253			_aEuropean heart journal. Acute cardiovascular care
260			_c2021
260			_fFY2022
265			_saheadofprint
265			_sppublish
266			_d2021-03-10
268			_aEuropean Heart Journal: Acute Cardiovascular Care. 2021 Feb 04
269			_fFY2021
520			_aAIMS: Primary percutaneous coronary intervention (pPCI) is the gold standard, guideline-recommended revascularization strategy in patients presenting with ST-elevation myocardial infarction (STEMI). However, there are limited data on its use and effectiveness among patients with active cancer presenting with STEMI.
520			_aCONCLUSION: Primary percutaneous coronary intervention is underutilized in STEMI patients with current cancer despite its significantly lower associated rates of in-hospital all-cause mortality and MACCE that is comparable to patients without cancer. Further work is required to assess the long-term benefit and safety of pPCI in this high-risk group. Copyright Published on behalf of the European Society of Cardiology. All rights reserved. (c) The Author(s) 2021. For permissions, please email: [email protected].
520			_aMETHODS AND RESULTS: All STEMI hospitalizations between 2004 and 2015 from the National Inpatient Sample were retrospectively analysed, stratified by cancer type. Propensity score matching was performed to estimate the average treatment effect of pPCI in each cancer on in-hospital adverse events, including major adverse cardiovascular and cerebrovascular events (MACCE) and its individual components, and compare treatment effect between cancer and non-cancer patients. Out of 1 870 815 patients with STEMI, 38 932 (2.1%) had a current cancer diagnosis [haematological: 11 251 (28.9% of all cancers); breast: 4675 (12.0%); lung: 9538 (24.5%); colon: 3749 (9.6%); prostate: 9719 (25.0%)]. Patients with cancer received pPCI less commonly than those without cancer (from 54.2% for lung cancer to 70.6% for haematological vs. 82.3% in no cancer). Performance of pPCI was strongly associated with lower adjusted probabilities of MACCE and all-cause mortality in the cancer groups compared with the no cancer group. There was no significant difference in estimated average pPCI treatment effect between the cancer groups and non-cancer group.
546			_aEnglish
650			_a*Neoplasms
650			_a*Percutaneous Coronary Intervention
650			_a*ST Elevation Myocardial Infarction
650			_aHospitals
650			_aHumans
650			_aMale
650			_aNeoplasms/co [Complications]
650			_aNeoplasms/ep [Epidemiology]
650			_aNeoplasms/th [Therapy]
650			_aPropensity Score
650			_aRetrospective Studies
650			_aST Elevation Myocardial Infarction/di [Diagnosis]
650			_aST Elevation Myocardial Infarction/ep [Epidemiology]
650			_aST Elevation Myocardial Infarction/su [Surgery]
650			_aTreatment Outcome
651			_aMedStar Heart & Vascular Institutena
657			_aJournal Article
700			_aBarac, Ana
790			_aAlkhouli M, Barac A, Bhatt DL, Elgendy IY, Khan SU, Kontopantelis E, Kwok CS, Mamas MA, Mohamed MO, Shoaib A, Van Spall HGC
856			_uhttps://dx.doi.org/10.1093/ehjacc/zuaa032 _zhttps://dx.doi.org/10.1093/ehjacc/zuaa032
942			_cART _dArticle
999			_c6225 _d6225